SCHEMBL24285945

SCHEMBL24285945

Nc1nc2ccc(-c3ccc4cc[nH]c4c3)cn2c1C(=O)[C@@H]1C[C@@H]1F

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LRRK2 Q5S007 6/20 0.40
▸ MPO P05164 6/20 0.38
▸ ABL1 P00519 8/20 0.37
▸ RIPK2 O43353 1/20 0.37
▸ PI4K2A Q9BTU6 1/20 0.36
▸ PIK3CD O00329 3/20 0.36
▸ EGFR P00533 3/20 0.36
▸ HCK P08631 3/20 0.36
▸ SRC P12931 3/20 0.36
▸ KDR P35968 3/20 0.36
▸ PIK3CA P42336 3/20 0.36
▸ PIK3CB P42338 3/20 0.36
▸ MTOR P42345 3/20 0.36
▸ PIK3CG P48736 3/20 0.36
▸ EPHB4 P54760 3/20 0.36
▸ PRKDC P78527 3/20 0.36
▸ LCK P06239 1/20 0.35
▸ BTK Q06187 1/20 0.35
▸ KCNH2 Q12809 2/20 0.35
▸ CDK4 P11802 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29537630 1.00 LRRK2 (0.40) LRRK2MPOABL1RIPK2PI4K2A
SCHEMBL29536913 0.93 LRRK2 (0.42) LRRK2ABL1PI4K2APIK3CDEGFR
SCHEMBL29537329 0.93 LRRK2 (0.42) LRRK2ABL1PI4K2APIK3CDEGFR
SCHEMBL29536982 0.93 LRRK2 (0.42) LRRK2ABL1PI4K2APIK3CDEGFR
SCHEMBL24285854 0.93 LRRK2 (0.42) LRRK2ABL1PI4K2APIK3CDEGFR
SCHEMBL24285976 0.93 LRRK2 (0.42) LRRK2ABL1PI4K2APIK3CDEGFR
SCHEMBL24286681 0.93 LRRK2 (0.42) LRRK2ABL1PI4K2APIK3CDEGFR
SCHEMBL24286022 0.93 LRRK2 (0.42) LRRK2ABL1PI4K2APIK3CDEGFR
SCHEMBL29537782 0.93 LRRK2 (0.42) LRRK2ABL1PI4K2APIK3CDEGFR
SCHEMBL24285977 0.84 LRRK2 (0.59) LRRK2ABL1PIK3CDEGFRHCK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4214207-A1 2-AMINO-3-CARBONYL IMIDAZOPYRIDINE AND PYRAZOLOPYRIDINE COMPOUNDS 1st Biotherapeutics, Inc. (KR) 2023-07-26 — — EP claimed
US-11744824-B2 2-amino-3-carbonyl imidazopyridine and pyrazolopyridine compounds 1ST Biotherapeutics, Inc. (KR) 2023-09-05 — — US disclosed
US-11744824-B2 2-amino-3-carbonyl imidazopyridine and pyrazolopyridine compounds 1ST Biotherapeutics, Inc. (KR) 2023-09-05 — — US disclosed
US-20220087985-A1 2-AMINO-3-CARBONYL IMIDAZOPYRIDINE AND PYRAZOLOPYRIDINE COMPOUNDS 1ST Biotherapeutics, Inc. (KR) 2022-03-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11744824-B2 2-amino-3-carbonyl imidazopyridine and pyrazolopyridine compounds NLRP3, NLRP1, KCNJ2 LRRK2 538/4885MPO 199/4885ABL1 966/4885
US-20220087985-A1 2-AMINO-3-CARBONYL IMIDAZOPYRIDINE AND PYRAZOLOPYRIDINE COMPOUNDS NLRP3, NLRP1, KCNJ2 LRRK2 538/4885MPO 199/4885ABL1 966/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback